Product Name: PAK2 (127-133) pY130
Product Number: PE-04AOK99
| Size: | 200 µg | Price: | 47.00 | |
| 1 mg | $US | 94.00 | ||
| 5 mg | 206.00 |
Peptide Name: PAK2 (127-133) pY130
Product Use: Services as a blocking peptide for use with the PAK2-pY130 rabbit polyclonal antibody (Cat. No.: AB-PK751) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located at the end of the PBD (p21-binding domain) in the N-terminal third of the protein. Y130 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LKF-pY-DSN
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Product Use: Services as a blocking peptide for use with the PAK2-pY130 rabbit polyclonal antibody (Cat. No.: AB-PK751) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located at the end of the PBD (p21-binding domain) in the N-terminal third of the protein. Y130 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LKF-pY-DSN
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1139.16 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PAK2 - pY130 phosphosite-specific antibody (Cat. No.: AB-PK751)
Peptide Molecular Mass Calculated: 1139.16 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PAK2 - pY130 phosphosite-specific antibody (Cat. No.: AB-PK751)
Scientific Background: PAK2 (PAK65) is a protein-serine/threonine kinase of the STE group and STE20 family. It functions in the regulation of several cellular processes including cytoskeletal reorganization, cell motility, cell cycle progression, apoptosis, and cellular proliferation. Under conditions that promotes cell growth and survival, PAK2 is activated by binding small G proteins. Binding of GTP-bound Cdc42 or Rac1 to the autoregulatory region releases monomers from the autoinhibited dimer, enables phosphorylation of T402 and allows the kinase domain to adopt an active structure. Phosphorylation at Y130, S141 and T402 increases phosphotransferase activity. It phosphorylates MAPK4 and MAPK6 ,c-Jun, histone H4, BAD, ribosomal protein S6, and MBP. Additionally, it associates with ARHGEF7 and GIT1 to perform kinase-independent functions such as spindle orientation control during mitosis. Apoptotic stimuli (e.g. DNA damage) induce the cleavage of PAK2 by caspases, generating the constitutively active p34 fragment that subsequently translocates to the nucleus and stimulates apoptosis via the JNK signalling pathway and phosphorylates MKNK1 to reduces cellular translation. PAK2 may be an oncoprotein (OP). Significantly elevated S20 phosphorylated PAK2 was observed in ovarian cancer cell lines. In addition, knockdown of PAK2 expression in ovarian cancer cell lines reduces cell migration and invasion without affecting cell proliferation or apoptosis. Elevated PAK2 and pPAK2 expression have also been demonstrated in human gastric cancer cell lines. Furthermore, elevated PAK2 and pPAK2 expression have been correlated with several unfavourable variables in patients with gastric cancer including higher tumour depth, greater extent of metastasis, advanced tumour stage and significantly lower survival rates.
© Kinexus Bioinformatics Corporation 2017